The mechanism by which active inflammation occurs in parallel with immunosuppression in the tumor microenvironment has been identified. Results showed reduced gene expression of regulatory T cell involved in immunosuppression. Cancer treatment employing EP2/EP4 inhibitors might benefit some cancer patients.
